Oncternal edges up as late-stage trial of cancer drug begins

Oncternal Therapeutics

27/09/2022 19:21

** Shares of Oncternal Therapeutics Inc  ONCT.O  up 1.3% at
$0.80 in afternoon trade
    ** Co says it has initiated a late-stage study of its
experimental drug, zilovertamab, for treatment of
relapsed/refractory mantle cell lymphoma (MCL)  urn:newsml:reuters.com:*:nGNX2Z2y0N
    ** Plans to open between 50 and 100 sites globally for the
study - Co
    ** MCL is a type of cancer that affects lymphatic system,
which is a part of the body's immune system
    ** Including session's move, stock down ~65% YTD
 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))